Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity

Area of Science:

• Neuroscience
• Genetics
• Pathology

Background:

• Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder.
• It stems from CAG trinucleotide repeat expansions in the huntingtin (Htt) gene, leading to an elongated polyglutamine (PolyQ) tract.
• Striatal pathology, including neuronal loss and compartment degeneration, characterizes HD, impairing cognitive, motor, and speech functions.

Purpose of the Study:

• To review and discuss neurodegenerative patterns in the HD striatum.
• To explore the roles of huntingtin-related and striatum-enriched proteins in HD pathogenesis.
• To elucidate potential mechanisms of striatal neurodegeneration in Huntington's disease.

Main Methods:

• Literature review and synthesis of existing clinical and experimental evidence.
• Analysis of neuropathological findings in Huntington's disease patients.
• Discussion of protein interactions and their contribution to neurotoxicity and neuroprotection.

Main Results:

• Striatal pathology in HD involves loss of medium spiny neurons and parvalbumin-expressing interneurons.
• Neurodegeneration affects both striosome and matrix compartments within the striatum.
• Multiple pathophysiological mechanisms are implicated in striatal neurodegeneration, involving various Htt-related and striatal proteins.

Conclusions:

• The precise cause of striatal pathology in HD remains incompletely understood.
• Huntingtin protein mutations and associated protein interactions play a critical role in HD pathogenesis.
• Further research into striatal-enriched proteins may reveal novel therapeutic targets for Huntington's disease.